A key challenge for therapeutic application of RNA interference is to efficiently deliver synthetic small interfering RNAs (siRNAs) into target cells that will lead to the knockdown of the target transcript (functional siRNA delivery). To facilitate rational development of nonviral carriers, we have investigated by imaging, pharmacological and genetic approaches the mechanisms by which a cationic lipid carrier mediates siRNA delivery into mammalian cells. We show that ∼95% of siRNA lipoplexes enter the cells through endocytosis and persist in endolysosomes for a prolonged period of time. However, inhibition of clathrin-, caveolin-, or lipid-raft-mediated endocytosis or macropinocytosis fails to inhibit the knockdown of the target transcript...
The large molecular weight, poly-anionic, and labile nature of small interfering RNA (siRNA) necessi...
Delivering nucleic acids into the endothelium has great potential in treating vascular diseases. How...
Most delivery systems for small interfering RNA therapeutics depend on endocytosis and release from ...
RNA interference (RNAi) is a method that can be used to treat various medical conditions. This metho...
Recent research has focused on exploiting the small interfering ribonucleic acid (siRNA) molecule in...
Design of an efficient delivery system is a generally recognised bottleneck in translation of siRNA ...
Cationic lipids are exploited as vectors ('lipoplexes') for delivering nucleic acids, including gene...
Cationic lipid- and polymer-based nanodevices are considered appropriate alternatives for virus-base...
Cationic lipid- and polymer-based nanodevices are considered appropriate alternatives for virus-base...
Cationic lipids are exploited as vectors ('lipoplexes') for delivering nucleic acids, including gene...
A central hurdle in developing small interfering RNAs (siRNAs) as therapeutics is the inefficiency o...
Non-viral vectors such as cationic lipids are capable of delivering nucleic acids, including genes, ...
Non-viral vectors such as cationic lipids are capable of delivering nucleic acids, including genes, ...
ABSTRACT: Small interfering RNAs (siRNAs) of 19-25 bp mediate the cleavage of complementary mRNA, le...
Delivery of short interfering RNAs (siRNAs) remains a key challenge in the development of RNA interf...
The large molecular weight, poly-anionic, and labile nature of small interfering RNA (siRNA) necessi...
Delivering nucleic acids into the endothelium has great potential in treating vascular diseases. How...
Most delivery systems for small interfering RNA therapeutics depend on endocytosis and release from ...
RNA interference (RNAi) is a method that can be used to treat various medical conditions. This metho...
Recent research has focused on exploiting the small interfering ribonucleic acid (siRNA) molecule in...
Design of an efficient delivery system is a generally recognised bottleneck in translation of siRNA ...
Cationic lipids are exploited as vectors ('lipoplexes') for delivering nucleic acids, including gene...
Cationic lipid- and polymer-based nanodevices are considered appropriate alternatives for virus-base...
Cationic lipid- and polymer-based nanodevices are considered appropriate alternatives for virus-base...
Cationic lipids are exploited as vectors ('lipoplexes') for delivering nucleic acids, including gene...
A central hurdle in developing small interfering RNAs (siRNAs) as therapeutics is the inefficiency o...
Non-viral vectors such as cationic lipids are capable of delivering nucleic acids, including genes, ...
Non-viral vectors such as cationic lipids are capable of delivering nucleic acids, including genes, ...
ABSTRACT: Small interfering RNAs (siRNAs) of 19-25 bp mediate the cleavage of complementary mRNA, le...
Delivery of short interfering RNAs (siRNAs) remains a key challenge in the development of RNA interf...
The large molecular weight, poly-anionic, and labile nature of small interfering RNA (siRNA) necessi...
Delivering nucleic acids into the endothelium has great potential in treating vascular diseases. How...
Most delivery systems for small interfering RNA therapeutics depend on endocytosis and release from ...